Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | BAX | Q07812 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621330 | 0.85 | ALDH1A1 (0.53) | LMNAKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31621333 | 0.85 | ALDH1A1 (0.53) | LMNAKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16838775 | 0.84 | L3MBTL1 (0.53) | LMNAGAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL16838770 | 0.84 | LTA4H (0.44) | LTA4HTSHRLMNAGAAKMT2A | |
| SCHEMBL30879457 | 0.84 | KDM4E (0.53) | LMNAGAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL15096345 | 0.80 | LYN (0.57) | LMNAGAAKMT2AMAOAALDH1A1 | |
| SCHEMBL16838771 | 0.80 | SCN9A (0.42) | LTA4HLMNAALDH1A1CA1CA2 | |
| SCHEMBL30879494 | 0.80 | NPC1 (0.41) | KMT2AALDH1A1 | |
| SCHEMBL21903921 | 0.78 | PARP10 (0.45) | LMNAGAAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10965186 | 0.77 | CYP19A1 (0.41) | LTA4HTSHRKMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068985-A1 | 1-(1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| US-11155539-B2 | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-26 | — | — | US | disclosed |
| US-20200123141-A1 | 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079042-A1 | 4-PYRIDINYLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| EP-2141171-A1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOAMINO AND ANTIFUNGAL AGENT CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141171-A1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOAMINO AND ANTIFUNGAL AGENT CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155539-B2 | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | LTA4H 2073/4885TSHR 1780/4885LMNA 3324/4885 |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | LTA4H 2577/4885TSHR 3597/4885LMNA 3822/4885 |
| US-20200123141-A1 | 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament | GRIN2A, GRIN2C, GRIN3A | LTA4H 2073/4885TSHR 1780/4885LMNA 3324/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | LTA4H 1316/4885TSHR 2534/4885LMNA 2506/4885 |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | LTA4H 3986/4885TSHR 4443/4885LMNA 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.